स्थापित सोने की कीमत उपकरण!
ऐतिहासिक स्वर्ण रजत मूल्य
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
1979
1978
1977
1976
1975
1974
1973
1972
1971
1970
1969
1968
|
1977/08/08
| अमरीकी डालर/ औंस | |
| Gold | 146.15 | |
| Silver | 456.5 |
Gold ऐतिहासिक गोल्ड मूल्य चार्ट और ग्राफ़
360 दिन ग्राफ ,
1 Ounce Gold=? USD
Silver रजत ऐतिहासिक मूल्य चार्ट और ग्राफ़
360 दिन ग्राफ ,
1 Ounce Silver=? USD
सोने की खबर:
- New colorectal cancer treatment approved in the U. S. - Takeda
OSAKA, Japan and CAMBRIDGE, Massachusetts, November 8, 2023 – Takeda (TSE:4502 NYSE:TAK) today announced that the U S Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin
- FRUZAQLA® (fruquintinib) for Previously Treated mCRC
For adults with metastatic colorectal cancer (mCRC), FRUZAQLA is an innovative and convenient oral treatment with proven survival results that can be taken after chemotherapy and other anti-cancer medications FRUZAQLA is a targeted therapy for people living with previously treated mCRC FRUZAQLA is not chemotherapy
- FDA approves fruquintinib in refractory metastatic colorectal cancer
On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc ) for adult patients with metastatic colorectal cancer (mCRC) who received prior
- FRUZAQLA® (fruquintinib) Access Guide
Please see page 3 for information about Takeda Oncology Here2Assist® Access Guide INDICATION FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an
- Takeda Receives U. S. FDA Approval of FRUZAQLA™ (fruquintinib) for . . .
Takeda (TSE:4502 NYSE:TAK) today announced that the U S Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted th
- FDA signs off on Takedas colorectal cancer drug Fruzaqla - Fierce Pharma
Takeda scores FDA green light for colorectal cancer drug Fruzaqla, 10 months after acquiring its rights in $1 1B deal with Hutchmed By Kevin Dunleavy Nov 9, 2023 10:54am
- Fruzaqla (fruquintinib): Prescribing Information, Dosage Side Effects . . .
FRUZAQLA (fruquintinib) capsules for oral administration contain 1 mg or 5 mg of fruquintinib The inactive ingredients are corn starch, microcrystalline cellulose, and talc The 1 mg capsule shell contains FD C Yellow No 5 (tartrazine), FD C Yellow No 6 (sunset yellow FCF), gelatin, and titanium dioxide Takeda Live Chat
- New colorectal cancer treatment approved in the U. S. - Takeda Oncology
Please see FRUZAQLA (fruquintinib) full Prescribing Information About CRC CRC is a cancer that starts in either the colon or rectum According to the International Agency for Research on Cancer, CRC is the third most prevalent cancer worldwide, associated with more than 935,000 deaths in 2020 7 In the U S , it is estimated that 153,000 patients will be diagnosed with CRC and 53,000 deaths
- FRUZAQLA Receives European Commission Approval for Metastatic . . . - Takeda
Takeda Receives U S FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer [Press Release] Available here Dasari NA, et al Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Lancet
- Takeda bags FDA okay for Fruzaqla in colorectal cancer
Takeda said that Fruzaqla (fruquintinib) has been cleared for use in adults with CRC who have been previously treated with chemotherapy, an anti-VEGF drug, and – if appropriate – an anti-EGFR
|
|
सोने की कीमत, सोना खरीदने, बेचने सोना ©2005-2009
|Currency Exchange Rate
|disclaimer
|